Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
13.04.23
/
50%
€33.50
Target price
13.04.24
€59.72
Performance (%)
-29.85%
End price
14.04.24
€23.50
Summary
This prediction ended on 14.04.24 with a price of €23.50. The prediction for Intellia Therapeutics Inc disappointed with a performance of -29.85%. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | 8.234% | 8.234% | 20.128% |
| iShares Core DAX® | -3.141% | 1.269% | 16.367% |
| iShares Nasdaq 100 | -3.518% | -1.355% | 2.670% |
| iShares Nikkei 225® | -3.396% | 3.283% | 17.041% |
| iShares S&P 500 | -2.943% | -0.533% | 1.373% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten